NCT02346955终止1 期
A Phase 1, Open-Label, Multicenter, Multi-Dose Escalation Study of CM-24 (MK-6018) as Monotherapy and In Combination With Pembrolizumab (MK-3475) in Subjects With Selected Advanced or Recurrent Malignancies
适应症
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 入组人数
- 27
- 试验地点
- 5
- 主要终点
- Number of participants with Adverse Events (AEs)
研究概览
简要总结
The purpose of this study is to evaluate the safety and tolerability of humanized IgG4 (kappa) isotype monoclonal antibody against CEACAM1 (CM-24 [MK-6018]), administered intravenously as monotherapy and in combination with Pembrolizumab (MK-3475), in participants with selected advanced or recurrent malignancies. Escalating multiple doses will be evaluated to determine the recommended dose for Phase 2 clinical studies.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Males and females ≥18 years of age
- •Participants in the Dose Escalation portion must have one of the following advanced or recurrent malignancies: gastrointestinal (colorectal or gastric); ovarian; melanoma; non-small cell lung adenocarcinoma; or bladder.
- •Participants in the Monotherapy Expansion Cohort must have one of the following advanced or recurrent malignancies: cutaneous melanoma showing primary progression following treatment with an anti-programmed cell death (PD) or anti-PDL1 regimen; or anti-PD1 or anti-PD-L1 treatment-naïve colorectal or gastric cancer, including gastroesophageal junction cancer of Siewert Type II and Type III.
- •Participants in the Combination Expansion Cohorts must have one of the following advanced or recurrent malignancies: non-small cell lung adenocarcinoma or cutaneous melanoma showing primary progression following treatment with an anti-PD1 or anti-PD-L1 regimen; or anti-PD1 or anti-PD-L1 treatment-naïve colorectal or gastric cancer, including gastroesophageal junction cancer of Siewert Type II and Type III.
- •Melanoma with BRAF V600E or V600K mutation-positive melanoma must have progressed on, or were intolerant to, prior BRAF- or MEK-inhibitor therapy
- •Must have at least 1 measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 with progressing or new tumors since last antitumor therapy
- •Must have adequate hematologic, renal, and liver function
- •Eastern Cooperative Oncology Group (ECOG) performance status 0-1
- •Females must not be pregnant (negative human chorionic gonadotropin test within 72 hours prior to receiving the first dose of study medication) or breastfeeding
- •Women of childbearing potential and male participants must agree to use adequate contraception throughout the study and for up to 180 days after study treatment
- •An estimated life expectancy of at least 3 months
- •Must consent to provide an archival tumor biopsy sample at any time point from screening to study exit
- •Must consent to allow the acquisition of new tissue biopsy samples during the study
排除标准
- •History of severe hypersensitivity reactions or immune related adverse events to other monoclonal antibodies
- •History of other active malignancy within the prior 2 years
- •History of insulin-dependent or uncontrolled Diabetes Mellitus
- •History of inflammatory bowel disease
- •Autoimmune disorders
- •Known HIV and/or Hepatitis B or C infections
- •Known systemic bleeding or platelet disorder
- •Receipt of live vaccines with 4 weeks (28 days) of study
- •History or evidence of non-infectious pneumonitis that required steroids or current pneumonitis
结局指标
主要结局
Number of participants with Adverse Events (AEs)
时间窗: From time of first dose until the end of follow-up (up to 123 weeks)
Number of participants discontinuing study drug due to AEs
时间窗: From time of first dose until the end of follow-up (up to 105 weeks)
Number of participants with a Dose Limiting Toxicity (DLT)
时间窗: From time of first dose until the end of follow-up (up to 12 weeks)
次要结局
- Maximum drug concentration in serum/plasma (Cmax)(For Cycles 1-35: all infusions at pre-infusion. For Cycle 1 first & fourth infusion: at end of infusion; 1, 4, 8 hours post-infusion; and Days 2, 3, 5, 8 post-infusion. For Cycle 1 fourth infusion also at Days 15, 22, 36 post-infusion.)
- Time to reach Cmax in serum/plasma (Tmax)(For Cycles 1-35: all infusions at pre-infusion. For Cycle 1 first & fourth infusion: at end of infusion; 1, 4, 8 hours post-infusion; and Days 2, 3, 5, 8 post-infusion. For Cycle 1 fourth infusion also at Days 15, 22, 36 post-infusion.)
- Terminal-phase elimination half-life in serum/plasma (t1/2)(For Cycles 1-35: all infusions at pre-infusion. For Cycle 1 first & fourth infusion: at end of infusion; 1, 4, 8 hours post-infusion; and Days 2, 3, 5, 8 post-infusion. For Cycle 1 fourth infusion also at Days 15, 22, 36 post-infusion.)
- Area under the plasma/serum concentration versus time curve from time zero to infinity (AUC 0-∞)(For Cycles 1-35: all infusions at pre-infusion. For Cycle 1 first & fourth infusion: at end of infusion; 1, 4, 8 hours post-infusion; and Days 2, 3, 5, 8 post-infusion. For Cycle 1 fourth infusion also at Days 15, 22, 36 post-infusion.)
- Area under the plasma/serum concentration versus time curve from time zero to the last measured time (AUC 0-T)(For Cycles 1-35: all infusions at pre-infusion. For Cycle 1 first & fourth infusion: at end of infusion; 1, 4, 8 hours post-infusion; and Days 2, 3, 5, 8 post-infusion. For Cycle 1 fourth infusion also at Days 15, 22, 36 post-infusion.)
- Objective Response Rate (ORR) defined using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria(From time of screening until the end of follow-up (up to 123 weeks))
- Time from ORR to disease progression or death (DOR)(From time of screening until the end of follow-up (up to 123 weeks))
研究者
研究点 (5)
Loading locations...
相似试验
已完成
4 期
Study of Combined Therapy IVIG-SN 10% and Acetylsalicylic Acid in Kawasaki DiseaseKawasaki DiseaseNCT04003844Green Cross Corporation45
已完成
1 期
Study To Evaluate The Safety, Tolerability And Immunogenicity Of 4 mg Of ITI-3000 In Patients With Polyomavirus-Positive Merkel Cell Carcinoma (MCC)Merkel Cell CarcinomaNCT05422781Immunomic Therapeutics, Inc.6
进行中（未招募）
1 期
A clincal study to evaluate the safety of a polio vaccine type 2 given orally in healthy children aged 1 to 5 years previously treated with inactivated polio vaccine in Lithuaniaevaluation of safety of SABIN mOPV2 in healthy IPV-vaccinated children of 1 – 5 years of age (Polio disease)MedDRA version: 18.0Level: LLTClassification code 10036016Term: Poliomyelitis NOSSystem Organ Class: 100000004862EUCTR2015-003544-39-LTFIDEC - Fighting Infectious Diseases in Emerging Countries
进行中（未招募）
1 期
A vaccine study in healthy adults to evaluate the safety and immune response of a licensed oral polio vaccine containing the polio vaccine 2 straiPolio diseaseMedDRA version: 18.0Level: HLTClassification code 10036017Term: Poliomyelitis viral infectionsSystem Organ Class: 100000004862EUCTR2015-003325-33-BEniversity of Antwerp100
进行中（未招募）
1 期
A vaccine study in healthy adults to evaluate the safety and immune response of a licensed oral polio vaccine containing 3 polio vaccine strains.Historic tOPV can result in the emergence of circulating vaccine-derived polioviruses (cVDPVs): the attenuated strains of poliovirus from the vaccine infect un-immunized individuals, replicate, circulate in the population, and may eventually mutate enough to become virulent and effect vaccine-associated paralytic poliomyelitis (VAPP).MedDRA version: 18.0Level: HLTClassification code 10036017Term: Poliomyelitis viral infectionsSystem Organ Class: 100000004862EUCTR2015-003324-32-BEniversity of Antwerp128